Antipsychotic use tied to acute kidney injury, increasing pressure on nursing home reduction effortsAugust 20, 2014
Older people who take antipsychotic medications are at a markedly increased risk of acute kidney injury, according to newly published research findings out of Canada. The study further supports ongoing efforts to reduce the number of nursing home residents on these drugs.
Elderly patients taking antipsychotics should be carefully monitored, especially after they first start taking the medication, due to a higher risk of hospitalization, a new study finds.
AstraZeneca is not entitled to more exclusivity with its antischizophrenic medication, an appeals court agreed last week. The company had claimed its drug, Seroquel, deserved another three-year extension under the Food Drug and Cosmetic Act.
Reducing the number of residents with dementia who are on antipsychotics starts with reassessment, experts advised at this week's American College of Health Care Administrators convocation In Orlando. The key is a multi-step process providers can follow.
Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based pharmaceutical company will pay the Bluegrass State $5.5 million.
Adding to the concerns about off-label use of antipsychotics, a new study has found four of the most common medications lack safety and effectiveness in older adults.
In response to a recent report from the Office of the Inspector General, a prominent psychiatrist is defending the practice of prescribing antipsychotic medications for nursing home residents with dementia.
Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.
AstraZeneca settles for $520 million following investigation into improper marketing of anti-psychotic drugApril 28, 2010
Pharmaceutical giant AstraZeneca has agreed to pay $520 million to end a federal investigation into its alleged illegal marketing of the drug Seroquel for off-label uses, according to reports from Washington.